BeOne Medicines company profile

ONC · NASDAQ · USD

Compare BeOne Medicines
$413.26Change from previous close: +0.48%Absolute change: +$1.97

Close · November 17, 2026

Company profile

BeOne Medicines has 12,000 employees and is headquartered in Basel, Switzerland.

BRUKINSA and TEVIMBRA are the medicines most closely associated with BeOne Medicines AG, which was known as BeiGene until its renaming in May 2025. BRUKINSA, a BTK inhibitor, is used against several blood cancers, while TEVIMBRA is an anti-PD-1 antibody that treats solid tumors and blood cancers. The pipeline includes candidates such as sonrotoclax, a Bcl-2 inhibitor, and zanidatamab, a HER2-targeted bispecific antibody. Partners include Amgen, BMS, Novartis and Luye Pharmaceutical, and the company holds an agreement with the U.S. government on access to cancer medicines.

In the fiscal year ended December 2025, revenue reached 5.3 billion USD, up 40.2% from the previous year, and net income was 286.9 million USD. The United States accounted for 53.9% of revenue and China for 31.4%, with Europe at 11.4%. The company had 12,000 employees and is headquartered in Basel, Switzerland. Its shares are also listed on the Shanghai Stock Exchange and the Hong Kong Stock Exchange.

Company facts

Industry
Biotechnology
Headquarters
94 Aeschengraben 27, 4051, Basel
Employees
12,000
Chief executive
John Oyler
Founded
2010
Fiscal year
January - December
Listing
ONC · NASDAQ
Currency
USD
ISIN
US07725L1026

BeOne Medicines and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
BeOne MedicinesONCUnited States$46.98B12,00017.8%52.7
Royalty PharmaRPRXUnited States$39.4B10064.4%45.4
Revolution MedicinesRVMDUnited States$37.27B883-853.0%—
argenxARGXUnited States$59.8B1,86331.9%32.9
Roivant SciencesROIVUnited States$28.64B721-3,226.3%—
InsmedINSMUnited States$26.96B1,664-41.7%—

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare BeOne Medicines with its competitors